Literature DB >> 21383091

Clonal spread of levofloxacin-resistant streptococcus pneumoniae invasive isolates in Madrid, Spain, 2007 to 2009.

Iciar Rodríguez-Avial1, Belén Ramos, Esther Ríos, Emilia Cercenado, María Ordobás, Juan Carlos Sanz.   

Abstract

Among 1,349 Streptococcus pneumoniae invasive isolates, 45 (3.3%) were levofloxacin resistant. Serotype distribution was as follows: 8 (n=32 isolates), 19A (n=4 isolates), 7F (n=3 isolates), 9V (n=2 isolates), 10A (n=1 isolate), 19F (n=1 isolate), 6B (n=1 isolate), and nontypeable (n=1 isolate). Levofloxacin-resistant isolates had dual mutations in the gyrA and parC genes. Serotype 8 strains corresponded to a capsular switching of the Sweden(15A)-25 clone. Levofloxacin resistance was also detected among multiresistant (ST276(19A), Spain9V-ST156, ST88(19F), and ST1542(6B)) and among usually antibiotic-susceptible (Netherlands7F-ST191, ST1201(19A), and ST2639(10A)) clones.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21383091      PMCID： PMC3088247          DOI： 10.1128/AAC.01380-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  20 in total

1.  Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia.

Authors:  Ross Davidson; Rodrigo Cavalcanti; James L Brunton; Darrin J Bast; Joyce C S de Azavedo; Pamela Kibsey; Christine Fleming; Donald E Low
Journal:  N Engl J Med       Date:  2002-03-07       Impact factor: 91.245

2.  Simplified protocol for pulsed-field gel electrophoresis analysis of Streptococcus pneumoniae.

Authors:  M C McEllistrem; J E Stout; L H Harrison
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

3.  ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype.

Authors:  R Muñoz; A G De La Campa
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

4.  Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae.

Authors:  X S Pan; J Ambler; S Mehtar; L M Fisher
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

Review 5.  Streptococcus pneumoniae: epidemiology and risk factors, evolution of antimicrobial resistance, and impact of vaccines.

Authors:  Joseph P Lynch; George G Zhanel
Journal:  Curr Opin Pulm Med       Date:  2010-05       Impact factor: 3.155

6.  A multilocus sequence typing scheme for Streptococcus pneumoniae: identification of clones associated with serious invasive disease.

Authors:  Mark C Enright; Brian G Spratt
Journal:  Microbiology (Reading)       Date:  1998-11       Impact factor: 2.777

Review 7.  The successful clone: the vector of dissemination of resistance in Streptococcus pneumoniae.

Authors:  K P Klugman
Journal:  J Antimicrob Chemother       Date:  2002-12       Impact factor: 5.790

8.  Quinolone resistance mechanisms in pneumococci.

Authors:  George M Eliopoulos
Journal:  Clin Infect Dis       Date:  2004-05-15       Impact factor: 9.079

9.  TARGETed surveillance: susceptibility of Streptococcus pneumoniae isolated from community-acquired respiratory tract infections in 2003 to fluoroquinolones and other agents.

Authors:  I Morrissey; A Colclough; J Northwood
Journal:  Int J Antimicrob Agents       Date:  2007-07-20       Impact factor: 5.283

10.  Genetic characterization of fluoroquinolone-resistant Streptococcus pneumoniae strains isolated during ciprofloxacin therapy from a patient with bronchiectasis.

Authors:  Adela G de la Campa; María-José Ferrandiz; Fe Tubau; Román Pallarés; Federico Manresa; Josefina Liñares
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191
View more
  13 in total

1.  Serotype distribution and antimicrobial resistance of invasive pneumococcal disease strains in the Comunidad Valenciana, Spain, during the winter of 2009-2010: low PCV7 coverage and high levofloxacin resistance.

Authors:  C M Gant; A W Rosingh; J L López-Hontangas; M van der Heijden; F González-Morán; J J E Bijlsma; E Canton
Journal:  Antimicrob Agents Chemother       Date:  2012-07-02       Impact factor: 5.191

2.  Fluoroquinolone-resistant pneumococci: dynamics of serotypes and clones in Spain in 2012 compared with those from 2002 and 2006.

Authors:  Arnau Domenech; Jose M Tirado-Vélez; Asunción Fenoll; Carmen Ardanuy; Jose Yuste; Josefina Liñares; Adela G de la Campa
Journal:  Antimicrob Agents Chemother       Date:  2014-02-10       Impact factor: 5.191

3.  Association of levofloxacin resistance with mortality in adult patients with invasive pneumococcal diseases: a post hoc analysis of a prospective cohort.

Authors:  C-I Kang; J-H Song; S H Kim; D R Chung; K R Peck; V Thamlikitkul; H Wang; T M So; P-R Hsueh; R M Yasin; C C Carlos; P H Van; J Perera
Journal:  Infection       Date:  2012-07-22       Impact factor: 3.553

Review 4.  Risk Factors for Drug-Resistant Cap in Immunocompetent Patients.

Authors:  Francisco Arancibia; Mauricio Ruiz
Journal:  Curr Infect Dis Rep       Date:  2017-03       Impact factor: 3.725

5.  In Vitro Activity of AZD0914, a Novel Bacterial DNA Gyrase/Topoisomerase IV Inhibitor, against Clinically Relevant Gram-Positive and Fastidious Gram-Negative Pathogens.

Authors:  Douglas J Biedenbach; Michael D Huband; Meredith Hackel; Boudewijn L M de Jonge; Daniel F Sahm; Patricia A Bradford
Journal:  Antimicrob Agents Chemother       Date:  2015-07-20       Impact factor: 5.191

6.  Recurrent pneumococcal invasive disease in the region of Madrid during a five-year period.

Authors:  J C Sanz; I Rodríguez-Avial; E Ríos; B Ramos; E Cercenado
Journal:  Infection       Date:  2013-12-22       Impact factor: 3.553

7.  Risk factors for levofloxacin-nonsusceptible Streptococcus pneumoniae in community-acquired pneumococcal pneumonia: a nested case-control study.

Authors:  C-I Kang; J-H Song; S H Kim; D R Chung; K R Peck; T M So; P-R Hsueh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-09-06       Impact factor: 3.267

8.  Seconeolitsine, the Novel Inhibitor of DNA Topoisomerase I, Protects against Invasive Pneumococcal Disease Caused by Fluoroquinolone-Resistant Strains.

Authors:  Jose Manuel Tirado-Vélez; David Carreño; David Sevillano; Luis Alou; José Yuste; Adela G de la Campa
Journal:  Antibiotics (Basel)       Date:  2021-05-13

9.  Global fluoroquinolone resistance epidemiology and implictions for clinical use.

Authors:  Axel Dalhoff
Journal:  Interdiscip Perspect Infect Dis       Date:  2012-10-14

10.  Serotype distribution and antibiotic resistance of Streptococcus pneumoniae isolates collected at a Chinese hospital from 2011 to 2013.

Authors:  Songyin Huang; Xiaoqiang Liu; Weisi Lao; Suhua Zeng; Huiqi Liang; Rihui Zhong; Xinlu Dai; Xiquan Wu; Hongyu Li; Yandan Yao
Journal:  BMC Infect Dis       Date:  2015-08-05       Impact factor: 3.090
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.